Editorial Board Disclosure Policy
(Last updated April 2023)
All editors responsible for recommending or making publication decisions are requested to disclose on an annual basis any potential conflict of interest, including current or recent financial relationships with any commercial entity whose products or services may be contained in the journal content.
The following competing interests were disclosed:
Simon H Pearce (Editor-in-Chief) – Professor Pearce consults for Worg Pharmaceuticals, Apitope International and Roivant Sciences. He is also a clinical trial lead for immunovant.
Saba P Balasubramanian – Dr Balasubramanian has received research grants from the NIHR and charities in UK relating to research in thyroid nodules and cancer.
Jens Mittag – Dr Mittag has received research grants from the German Research Council (DFG).
Romana Netea-Maier – Professor Netea-Maier has represented her institution as part of advisory boards and has given presentations or attended conferences sponsored by EISAI and Lilly. Her insitiution has received remuneration for her services within the lawfully permitted limits. She has received through her institution independent grants for investigator-initiated studies as well as travel expenses from EISAI.
Luca Persani – Professor Persani receives consulting fees from Merck, Sandoz, Recordati Rare Diseases and Pfizer.
Patrice Rodien – Dr Rodien has received exceptional honoraria from pharmaceutical firms for acting on expert boards.
The following editors reported no competing interests:
- Furio Pacini
Bioscientifica staff and freelancers working on the journal reported no conflicts of interest. Article authors' declarations are stated in each journal article. Referees must disclose any competing interests before agreeing to review any submission. For more information on the journal’s ethical policy, please read the ethical guidelines.
This policy follows the recommendations of the International Committee of Medical Journals Editors (ICMJE) and the Committee on Publication Ethics (COPE).
